Cellectis SA Stock Analysis & Ratings
738 Followers
CLLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.30 - $15.50
Previous Close$3.81
Volume4.60K
Average Volume (3M)140.88K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-1.5
Beta2.07
Next EarningsNov 15, 2022
EPS Forecast-$0.38
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$7.67
Smart Score6
EPS (TTM)-2.49
Shares Outstanding45,490,810
R-Squared0.38
Standard Deviation0.18
10 Day Avg. Volume82,284
30 Day Avg. Volume140,878
P/B Ratio0.72
P/S Ratio6.08
P/CF Ratio266.40
P/FCF Ratio-1.20
Total Debt$85.36M
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside91.99% Upside
Rating ConsensusHold
Alpha-0.04
Number of Analyst Covering4
Cellectis SA News
P/E Ratio Range
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $2.30 and its highest was $15.50 in the past 12 months.
What is Cellectis SA’s market cap?
Currently, no data Available
What is Cellectis SA’s price target?
The average price target for Cellectis SA is $7.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $11.00 ,the lowest forecast is $2.00. The average price target represents 91.99% Increase from the current price of $3.995.
The highest analyst price target is $11.00 ,the lowest forecast is $2.00. The average price target represents 91.99% Increase from the current price of $3.995.
What do analysts say about Cellectis SA?
Cellectis SA’s analyst rating consensus is a ‘Hold. This is based on the ratings of 4 Wall Streets Analysts.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Nov 15, 2022 which is in 92 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Aug 04, 2022. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.514 by $0.094.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Undervalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -$0.38.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 45,475,310 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.514. Following the earnings report the stock price went up 10.897%.
Which hedge fund is a major shareholder of Cellectis SA?
Among the largest hedge funds holding Cellectis SA’s share is Bpifrance SA. It holds Cellectis SA’s shares valued at 1M.
---
Cellectis SA Stock Analysis
Smart ScoreNeutral
1
2
3
4
5
6
7
8
9
10
Analyst Forecast
Hold
Average Price Target: $7.67
Blogger Sentiment
N/A
Currently Not Enough Data Available
Hedge Fund Holdings
N/A
Currently Not Enough Data Available
Insider Transactions
N/A
Currently Not Enough Data Available
Retail Investors
Very Negative
Last 7 Days ▼ 0.5% Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish 50% Bearish 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.51%
12-Months-Change
Fundamentals
Return on Equity
-50.93%
Trailing 12-Months
Asset Growth
-29.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cellectis SA
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
---
---